Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation

Aims Peripheral arterial disease (PAD) is highly prevalent in general population. Data on the prevalence of symptomatic PAD in patients with atrial fibrillation (AF) are limited, and the impact of PAD on adverse outcomes in AF patients is controversial. Our aims were: (i) to define the prevalence of symptomatic PAD in European AF patients and describe its associated clinical risk factors and (ii) to establish the relationship of PAD to adverse events in AF, especially all-cause death. Methods Atrial fibrillation patients enrolled in the EORP-AF Pilot study with data about PAD status were included in this analysis. Event rates were determined at 1-year follow-up. Results Peripheral arterial disease was recorded in 328 (11%) patients. Age ( P < 0.0001), hypertension ( P = 0.0059), diabetes mellitus ( P = 0.0001), chronic heart failure ( P < 0.0001), previous stroke/transient ischaemic attack ( P = 0.0060), and antiplatelet drug treatment ( P = 0.0001) were associated with the presence of PAD, while female gender was inversely associated ( P = 0.0002). Peripheral arterial disease patients had higher absolute rates of both cardiovascular (CV) and all-cause death (both P < 0.0001). On Kaplan–Meier analysis, risk of all-cause death was higher in PAD patients compared with those without PAD ( P < 0.0001), but PAD did not emerge as an independent risk factor for mortality on Cox regression analysis. A lower risk of all-cause death was associated with the prescription of statins ( P = 0.0019), angiotensin-converting enzyme inhibitors ( P = 0.0008), and calcium-channel blockers ( P = 0.0071). Conclusion Peripheral arterial disease is prevalent in 11% of AF patients and related to various atherosclerotic risk factors. Even if PAD is associated with higher risk of all-cause death on univariate analysis, this risk was significantly lowered and was no longer evident after adjusting for the use of CV prevention drugs.